Related Experiment Video

Updated: Aug 10, 2026

Intrauterine Telemetry to Measure Mouse Contractile Pressure In Vivo
07:03

Intrauterine Telemetry to Measure Mouse Contractile Pressure In Vivo

Published on: April 6, 2015

[The effect of tocolytic drugs on oxytocin-induced uterine contractility in vitro]

H Muñoz1, E Marusic

  • 1Departamento de Obstetricia y Ginecología, Hospital Clínico J. J. Aguirre, Chile.

Revista Chilena De Obstetricia Y Ginecologia
|January 1, 1992
PubMed

Insights

Calcium channel blockers effectively reduce oxytocin-induced uterine contractions. Their efficacy is dose-dependent and comparable to magnesium sulfate and ritodrine, with oxytocin activating a calcium-dependent potassium channel.

Area of Science:

  • Pharmacology
  • Physiology
  • Obstetrics

Background:

  • Oxytocin is a key hormone regulating uterine contractions.
  • Uterine hypercontractility is a concern in obstetric complications.
  • Calcium channels play a crucial role in smooth muscle contraction.

Purpose of the Study:

  • To investigate the efficacy of calcium channel blockers in inhibiting oxytocin-induced uterine contractions.
  • To compare the effects of calcium channel blockers with established tocolytic agents.
  • To identify potential ion channels involved in oxytocin's action on the uterus.

Main Methods:

  • In vitro or in vivo experimental models to induce uterine contractions with oxytocin.
  • Administration of varying doses of calcium channel blockers.
  • Comparative analysis with ritodrine and magnesium sulfate.
  • Electrophysiological or molecular techniques to identify ion channels.

Main Results:

  • Calcium channel blockers significantly inhibited oxytocin-induced uterine contractions.
  • The inhibitory effect was dose-dependent.
  • Efficacy was comparable to ritodrine and magnesium sulfate.
  • A calcium-dependent potassium channel, activated by oxytocin, was identified.

Conclusions:

  • Calcium channel blockers represent a viable therapeutic option for managing excessive uterine contractions.
  • The findings elucidate the role of calcium channels and potassium channels in uterine contractility regulation.
  • Oxytocin's mechanism involves the activation of a calcium-dependent potassium channel, offering a potential target for future interventions.

More Related Videos

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis06:22

Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis

Published on: September 1, 2019

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...